LEXICON PHARMACEUTICALS, INC. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 45/100
What the filing says
Lexicon Pharmaceuticals entered into a Loan and Security Agreement dated May 4, 2026 with Hercules Capital (agent) and other lenders for up to $100 million in term loan advances across three tranches: Tranche 1 (immediate), Tranche 2 (conditional), and Tranche 3 (discretionary). The facility is secured by substantially all assets, bears floating interest at Prime Rate plus a spread, requires repayment by maturity date, includes various covenants (cash maintenance, revenue targets, IP protection), and grants Hercules warrants to purchase common stock with a 2.0% warrant coverage tied to funded amounts.
Why this rating
Significant refinancing of existing debt (Oxford LSA payoff noted). Materially sized ($100M) relative to ~$170M market cap (59% of company size), but routine debt restructuring for pharma biotech. Neutral outlook: refinancing reduces immediate refinancing risk but introduces new covenants, cash requirements, and dilution via warrants.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.